Laval University publishes important research findings on plasmalogens in Parkinson’s disease model

Recent research from Laval University demonstrates the critical role of plasmalogens in Parkinson’s disease. The research revealed that treatment of plasmalogens in a mouse model of Parkinson’s disease had anti-inflammatory effects in the gut and neuroprotective properties. There is increased interest in the research community about the role of the gut in Parkinson’s disease and this recent publication highlights the potential role of plasmalogens in gut health.

The research was conducted using PPI-1011, a plasmalogen precursor drug that was invented by Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences. PPI-1011 is no longer being developed by Dr. Goodenowe since he recently designed and developed a new and improved natural version of the PPI-1011 drug: Prodrome-Neuro Plasmalogen Oil supplement which has the same plasmalogen elevating activity and strength, but has additional features not present in PPI-1011. Prodrome-Neuro Plasmalogen Oil was validated in humans recently and successfully raised target plasmalogen levels in the blood.